Early-Stage Results for AMG 509 (xaluritamig) Illustrate Expanding Potential of Amgen (AMGN)'s T-Cell Engagers in mCRPC THOUSAND OAKS, Calif., Oct. 16, 2023 /PRNewswire/ -- Amgen today announced the ...

THOUSAND OAKS, Calif., May 30, 2023 /PRNewswire/ -- Amgen (AMGN) today announced new research examining the use of Otezla ® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study and ...

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra (tarlatamab-dlle) for treating patients with small cell lung cancer (SCLC), who ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

Biotech company Amgen is investing $600 million into a new research center for its Thousand Oaks campus. The new site will create hundreds of jobs and feature advanced automation and digital ...

On Tuesday, Amgen Inc. (NASDAQ: AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines. The acquisition values Dark Blue ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab-cdon) as the first and only treatment for adult patients with Immunoglobulin ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An Amgen sign is seen at the company's headquarters in Thousand Oaks, California, U.S., November 6, 2019.